Compare ADMA Biologics Inc (ADMA) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Global X SuperDividend ETF — how do they compare? ADMA Biologics Inc trades at $9.2 (market cap $2.13B), while Global X SuperDividend ETF trades at $24.24. The key difference: Global X SuperDividend ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SDIV | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $26.34 |
52-Week Low | $7.60 | $22.90 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SDIV trades at $24.46, down 0.37% on the day, with a bullish technical signal driven by strong buy indicators despite bearish moving averages. The ETF offers a high dividend yield, recently paying $0.18 per share quarterly, attracting income-focused investors. Recent news highlights its role in diversified portfolios for retirees seeking steady cash flow, with a current yield around 9%.
Outlook is supported by yield appeal in a higher-rate environment, but risks include sensitivity to interest rates and limited tech exposure. Analysts view it as a diversification tool amid AI sector concentration, though valuation metrics are not fully disclosed. Institutional activity shows mixed signals with recent buying and selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
